MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1

Wu, Huijuan; Xiao, Zheng; Wang, Ke; Liu, Wenxin; Qin, Hao

doi:10.1016/j.bbrc.2013.10.053

Cited by 75 publications

(63 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are with the trend of studies indicating that some microRNAs, including the miR-145, are downregulated in ovarian cancer [65,66], and that cancer cells growth inhibition caused by quercetin may be correlated with the modulation of several miRs expression of [60,63,67,68].…”

Section: Chemoprotective Activities In Ovarian Cancer Cells Of Quercesupporting

confidence: 86%

Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells – A Mini-review

Kujawski¹,

Baraniak²,

Ożarowski³

et al. 2017

Altern Integr Med

View full text Add to dashboard Cite

Despite the increasing number of studies on the molecular actions of quercetin and curcumin, their anticancer efficacy, safety and molecular aspects of chemopreventive action in the ovarian cancer prophylaxis or treatment and also their potential in the sensitization to cytostatics used in the clinical practice remains still not clearly understood.Based on basic studies we have summarized evidences for inhibitory activities of several often studied plantorigin bio-active compounds (mostly quercetin and curcumin) against ovarian cancer cells proliferation, their mechanisms of action as well as their strong potential to sensitization of ovarian cancer cells to the presence of several platinum-based cytostatics -cisplatin and oxaliplatin. Up to date only several dietary, clinical (cohort and case-control) studies evaluating the association of some flavonoids (mostly nonisoflavones) and its subgroup components consumption and ovarian cancer risk were already performed. According to the researchers, there has been no association between ovarian cancer risk and total nonisoflavone flavonoids intake. There is a still an insufficient amount of data designed to explain the effect of quercetin or curcumin (alone or together) on ovarian cancer development and/or its chemotherapy. Obtained results provide limited support for an association between nonisoflavone flavonoids intake and ovarian cancer risk, therefore there is a need for further and more accurate studies to be confirmed. We are of the opinion that this paper will contribute to a better understanding of the molecular basis for positive interactions between concomitant usage of quercetin or curcumin with above-mentioned cytostatics and other bio-active agents. This work may also contribute to an increase in the number of preclinical studies or other clinical, dietary trials using these or other phenolic / alkaloid, plant-origin constituents in order to investigate efficiency and safety of pharmacotherapy of ovarian cancer patients.

show abstract

Section: Chemoprotective Activities In Ovarian Cancer Cells Of Quercesupporting

confidence: 86%

Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells – A Mini-review

Kujawski¹,

Baraniak²,

Ożarowski³

et al. 2017

Altern Integr Med

View full text Add to dashboard Cite

show abstract

“…It is shown that overexpressed miR-145 inhibits cell proliferation, invasion, and tumor growth, while promoting cell apoptosis in ovarian cancer. By negatively regulating expressions of its target genes, such as plasminogen activator inhibitor-1 (PAI-1), sex-determining region Y (SRY)-box 2 (Sox-2), IRS-1, c-Myc, and p70S6K1, miR-145 plays a critical role in these cellular processes [29,48,49]. The present study showed miR-145 was significantly down-regulated in ovarian cancer.…”

Section: Discussionmentioning

confidence: 62%

“…DNA methylation, chromosomal alterations, abnormal transcription, and posttranscriptional events were associated with the aberrant expression of miR-145. In recent years, aberrant expressions of miR-145 in ovarian cancer have already been described in related studies [15,[29][30][31]. However, due to the differences in the study design, sample size, sample type, and quantitative methods, the published data on miR-145 human cancers research have reached an inconsistent or discrepant conclusion.…”

Section: Introductionmentioning

confidence: 99%

Serum microRNA-145 as a novel biomarker in human ovarian cancer

et al. 2015

View full text Add to dashboard Cite

Ovarian cancer is one of the most threatening diseases among women in the world. Current detection methods are expensive and lack accuracy. Thus, a fast, non-invasive biomarker for detecting ovarian cancer is urgently needed. Compelling evidences have been demonstrated that microRNAs, a large family of single-stranded and non-protein-coding RNA molecules, can serve as useful biomarkers in cancer detection. In this study, the relative expressions of microRNA-145 (miR-145) in the serum of patients with ovarian cancer and healthy controls were investigated in an independent study. Subsequently, the diagnosis and prognosis value of miR-145 as a biomarker for ovarian cancer were examined. Furthermore, we performed a meta-analysis to summarize all the results from published studies and this study. Relative expressions of miR-145 were investigated in three independent groups (malignant ovarian cancer, benign ovarian tumor, and healthy controls), comprising a total of 270 participants. Receiver operating characteristic (ROC) curves and overall survival (OS) curves were conducted to compare miR-145 level and clinical characteristics among the three groups. The results showed that relative expressions of the serum miR-145 were significantly down-regulated in patients with malignant ovarian cancer and benign ovarian cancer, compared to healthy controls (P < 0.01). Serum miR-145 levels could discriminate patients with malignant ovarian cancer from healthy controls, with a power area under the curve (AUC) of 0.82 (95 % confidence interval (CI) = 0.77-0.88). Furthermore, patients with low serum levels of miR-145 had a significantly shorter median overall survival rate (hazard ratio (HR) = 1.81, 95 % CI = 1.03-3.17, P = 0.039). The meta-analysis yields good diagnostic performances of miR-145 in various cancers, with an AUC of 0.82 (95 % CI, 0.78-0.85). In conclusion, the present study suggested that miR-145 can potentially serve as an outstanding biomarker for ovarian and other human cancers detection.

show abstract

“…Growing evidence suggests that the aberrant expression of miRNAs may be involved in the pathogenesis of numerous cancers (11). Particularly in EOC, there have been a number of studies that have reported the differentially regulated miRNAs in cancer cells compared with normal controls, and have confirmed their critical role in cancer progression (12–14). For instance, Wang et al (12) revealed that miR-182 was upregulated in ovarian cancer tissues and cell lines, and could function as an oncogene to promote cancer cell growth, invasion and chemoresistance by targeting programmed cell death 4.…”

Section: Introductionmentioning

confidence: 96%

MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2

2016

View full text Add to dashboard Cite

MicroRNA (miRNA or miR)-298 has been reported to be downregulated and to modify the expression of the polycomb protein enhancer of zeste 2 (EZH2) in recurrent epithelial ovarian cancer (EOC). To date, no functional evidence of a miR-298-EZH2 axis in EOC has been documented. The present study aimed to investigate the associations of miR-298 and/or EZH2 expression with clinicopathological features of EOC patients, and revealed their roles in cell motility based on EOC cell lines. Reverse transcription-quantitative polymerase chain reaction was performed to detect the expression levels of miR-298 and EZH2 messenger RNA in human EOC tissues and cell lines. Wound healing and transwell assays were performed to determine the function of the miR-298-EZH2 axis on cell migration and invasion, respectively. Compared with normal tissues, miR-298 expression was significantly downregulated, while EZH2 expression was significantly upregulated, in human EOC tissues (both P=0.001). In addition, miR-298 downregulation and EZH2 upregulation were significantly associated with high clinical stage (both P=0.01) and pathological grade (both P=0.02) of EOC patients. Furthermore, the ectopic expression of miR-298 could efficiently inhibit cell migration and invasion. Notably, the overexpression of EZH2 could restore the cell migration and invasion abilities suppressed by miR-298. Our data offer convincing evidence that the dysregulation of the miR-298-EZH2 axis may be important in tumor progression of EOC patients. The present study also confirmed a tumor-suppressive role of miR-298 in modulating EOC cell motility by regulating the expression of EZH2, implying its potential as a novel miRNA-based therapeutic target for the treatment of human EOC.

show abstract

MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1

Cited by 75 publications

References 24 publications

Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells – A Mini-review

Basic Studies on Chemopreventive Properties of Quercetin and Curcumin and Other Plant-origin Compounds in Ovarian Cancer Cells – A Mini-review

Serum microRNA-145 as a novel biomarker in human ovarian cancer

MicroRNA-298 inhibits malignant phenotypes of epithelial ovarian cancer by regulating the expression of EZH2

Contact Info

Product

Resources

About